Sam Brusco, Associate Editor01.10.24
Dexcom announced that its new Stelo glucose sensor, which is meant for type 2 diabetes patients who don’t use insulin, has been submitted to the U.S. Food and Drug Administration (FDA) for review in Q4 2023.
The company said the Stelo sensor will have a 15-day wear time, cash-pay option, and accompanying software tailored to non-insulin users. Dexcom expects Stelo to launch in the U.S. this summer.
“Understanding glucose levels is key to unlocking our metabolic health, and Stelo will help users see first-hand how their health is affected by factors such as diet, exercise, sleep, and stress,” said Jake Leach, executive vice president and COO at Dexcom. “Through our expanding product portfolio, Dexcom is defining the future of sensing technology and empowering people to take control of health.”
The company also reported Q4 2023 revenue of at least $1.03 billion, a 26% increase above Q4 2022. For the fiscal year 2023, Dexcom expects about $3.62 billion preliminary, unaudited revenue, growing 24% over the prior year.
The U.S. market captured most of the sales with $765 million—another 26% hike—and $265 million from international proceeds. For 2024, the company predicts $4.15-4.35 billion in sales, representing growth of 16-21% over 2023.
Last month, Tandem Diabetes Care launched updated t:slim X2 insulin pump software with Dexcom G7 continuous glucose monitoring (CGM) integration in the U.S. Dexcom also launched G7’s integration with Beat Bionics’ iLet bionic pancreas in December.
The company said the Stelo sensor will have a 15-day wear time, cash-pay option, and accompanying software tailored to non-insulin users. Dexcom expects Stelo to launch in the U.S. this summer.
“Understanding glucose levels is key to unlocking our metabolic health, and Stelo will help users see first-hand how their health is affected by factors such as diet, exercise, sleep, and stress,” said Jake Leach, executive vice president and COO at Dexcom. “Through our expanding product portfolio, Dexcom is defining the future of sensing technology and empowering people to take control of health.”
The company also reported Q4 2023 revenue of at least $1.03 billion, a 26% increase above Q4 2022. For the fiscal year 2023, Dexcom expects about $3.62 billion preliminary, unaudited revenue, growing 24% over the prior year.
The U.S. market captured most of the sales with $765 million—another 26% hike—and $265 million from international proceeds. For 2024, the company predicts $4.15-4.35 billion in sales, representing growth of 16-21% over 2023.
Last month, Tandem Diabetes Care launched updated t:slim X2 insulin pump software with Dexcom G7 continuous glucose monitoring (CGM) integration in the U.S. Dexcom also launched G7’s integration with Beat Bionics’ iLet bionic pancreas in December.